Researchers test first drug to prevent the onset of chemotherapy-induced neuropathy

(IDIBELL-Bellvitge Biomedical Research Institute) Peripheral neuropathy is a very common side-effect of chemotherapy and may eventually lead to early discontinuation of treatment.Collaboration between research and industry led to the identification and successful testing of a new molecule capable of preventing this neurological complication.This molecule could potentially become the first existing treatment to prevent this frequent adverse effect and improve the quality of life of cancer patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

AbstractIncreases in cancer diagnosis have tremendous negative impacts on patients and their families, and major societal and economic costs. The beneficial effect of chemotherapeutic agents on tumor suppression comes with major unwanted side effects such as weight and hair loss, nausea and vomiting, and neuropathic pain. Chemotherapy-induced peripheral neuropathy (CIPN), which can include both painful and non-painful symptoms, can persist 6  months or longer after the patient’s last chemotherapeutic treatment. These peripheral sensory and motor deficits are poorly treated by our current analgesics with limited ...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
In conclusion, resolution of CIPN requires in vivo education of CD8+ T cells by exposure to cisplatin. Future studies should examine whether ex vivo CD8+ T cell education could be applied as a therapeutic strategy for treating or preventing CIPN in patients.
Source: Pain - Category: Anesthesiology Tags: Research Paper Source Type: research
This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern platinum-based chemotherapy. PATIENTS AND METHODS: Eligible TCS were
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
The objective of this study was to assess the relative contribution of a wider range of risk factors in the development of CIPN.MethodsThis analysis used the 6 ‐month data after starting chemotherapy from a larger prospective observational study on CIPN risk, prevalence, and quality of life. Patients were assessed at recruitment for possible CIPN risk factors, including prior history of neuropathies, current/past infectious diseases; neurotoxic medicatio n history; personal and treatment characteristics; smoking history, alcohol use, and vegetable/fruit intake. Neuropathy was assessed at 6‐months after starting chemoth...
Source: Brain and Behavior - Category: Neurology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: The evidence is insufficient to recommend acupuncture for the treatment or prevention of cipn. Further research is needed to evaluate the effects of acupuncture in the treatment of cipn. Given that acupuncture is considered safe and might provide relief for patients, it can be considered at the clinician's discretion. PMID: 31043820 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Chemotherapy-induced peripheral neuropathy (CIPN) can affect functional performance and quality of life considerably. Since balance training has proven to enhance physical function, it might be a promising str...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Determination of etiology in new-onset peripheral neuropathy is one of the most common clinical challenges in neurology. Peripheral neuropathies are quite common, especially among the elderly and in population-based studies, such that after 60 years of age more than 6% of the population will have developed neuropathy. The causes of neuropathy are diverse, with the most common being diabetes, infectious, nutritional, inflammatory, and hereditary. Despite the many causes of neuropathy, for a given patient, the specific etiology is often not discovered (ie, idiopathic/cryptogenic). Drug-induced peripheral neuropathies are als...
Source: JAMA Neurology - Category: Neurology Source Type: research
Recent albeit limited evidence suggests that body mass index (BMI) may be a modifiable risk factor to reduce the deleterious effects of chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
(Henry Ford Health System) NeurExo Sciences, LLC and Henry Ford Health System today announced the presentation of new data on exosomes at the International Society for Extracellular Vesicles (ISEV) 2019 Annual Meeting being held April 24-28, 2019 in Kyoto, Japan. Among their key findings, Henry Ford researchers demonstrated the ability of exosomes to suppress chemotherapy-induced peripheral neuropathy and enhance the anti-tumor effects of platinum drugs, which are commonly used to treat cancers.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Neurology | Peripheral Neuropathy